Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 2/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798353 | 0.89 | CYP2E1 (0.41) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL7219105 | 0.83 | CYP2E1 (0.49) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL3280017 | 0.82 | NCOA3 (0.42) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL6472029 | 0.81 | CYP2E1 (0.48) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL11385986 | 0.79 | NAAA (0.41) | CYP11B1CYP11B2HTTNCOA3ALDH1A1 | |
| SCHEMBL31421458 | 0.79 | CYP2D6 (0.47) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL6626248 | 0.79 | CYP2E1 (0.59) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL3921110 | 0.75 | CYP2E1 (0.32) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL15467814 | 0.75 | HTT (0.40) | HTTNCOA3KDM4EALDH1A1CDK1 | |
| SCHEMBL2982329 | 0.75 | HTR6 (0.48) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1120409-B1 | 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, DRUG COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-01-26 | — | — | EP | disclosed |
| CN-1173950-C | 2,3-Disubstituted pyridine derivatives, process for preparation thereof, drug compositions containing the same and intermediates for preparation | �ձ���ҩ��ʽ���� | 2004-11-03 | — | — | CN | disclosed |
| US-6765095-B2 | HETEROCYCLIC IMINES SUCH AS 2-PHENOXY-3-(3-(PYRIDIN-4-YL)-PROPOXY)PYRIDINE, FORMED BY ETHERIFICATION, AMINATION OR SULIFIDING, FOR USE AS PHOSPHODIESTERASE INHIBITORS | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2004-07-20 | — | — | US | disclosed |
| US-6683186-B2 | CONDENSATION, ETHERIFICATION; PHOSPHODIESTERASE INHIBITORS; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20030199554-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | KAWASAKI MOTOJI (JP) | 2003-10-23 | — | — | US | disclosed |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | KAWASAKI MOTOJI (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6555557-B1 | 2-(3-chlorophenoxy)-3-(3-(3-hydroxypyridin-5-yl)propoxy) -pyridine, for example; phosphodiesterase IV inhibitors | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| CN-1328547-A | 2,3-Disubstituted pyridine derivatives, process for preparation thereof, drug compositions containing the same and intermediates for preparation | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-12-26 | — | — | CN | disclosed |
| EP-1120409-A1 | 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, DRUG COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION | Dainippon Pharmaceutical Co., Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199554-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | NOX1, CYP4A11, PDE12 | CYP2E1 240/4885CYP2C8 482/4885CYP2D6 895/4885 |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | NOX1, CYP4A11, PDE12 | CYP2E1 240/4885CYP2C8 482/4885CYP2D6 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.